Semin Liver Dis 2005; 25(3): 311-320
DOI: 10.1055/s-2005-916322
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Overlap Syndromes

Ulrich Beuers1 , 2 , Christian Rust2
  • 1Professor of Medicine, Department of Medicine II - Grosshadern, Ludwig Maximilians-University of Munich, Munich, Germany
  • 2Department of Medicine II - Grosshadern, Ludwig Maximilians-University of Munich, Munich, Germany
Further Information

Publication History

Publication Date:
06 September 2005 (online)

ABSTRACT

In hepatology, the term overlap syndrome describes variant forms of the major hepatobiliary autoimmune diseases, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). Patients with overlap syndromes present with both hepatitic and cholestatic biochemical and histological features of AIH, PBC, and/or PSC, and usually show a progressive course toward liver cirrhosis and liver failure without adequate treatment. AIH-PBC overlap syndromes have been reported in almost 10% of adults with AIH or PBC, whereas AIH-PSC overlap syndromes were found in 6 to 8% of children, adolescents, and young adults with AIH or PSC. A minority of patients may also show transition from stable PBC to AIH, AIH to PBC, or AIH to PSC, as documented by single case reports and small case series. Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes includes anticholestatic therapy with ursodeoxycholic acid and immunosuppressive therapy with corticosteroids and azathioprine. In end-stage disease, liver transplantation is the treatment of choice.

REFERENCES

  • 1 Czaja A J. The variant forms of autoimmune hepatitis.  Ann Intern Med. 1996;  125 588-598
  • 2 Heathcote E J. Overlap syndromes. In: Bircher J, Beuhamou JP, McIntyre N, Rizzetto M, Rodès J Oxford Textbook of Clinical Hepatology, Vol. 2. Oxford, United Kingdom; Oxford University Press 1999: 1135-1140
  • 3 Woodward J, Neuberger J. Autoimmune overlap syndromes.  Hepatology. 2001;  33 994-1002
  • 4 Poupon R. Autoimmune overlapping syndromes.  Clin Liver Dis. 2003;  7 865-878
  • 5 Colombato L A, Alvarez F, Cote J, Huet P M. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis?.  Gastroenterology. 1994;  107 1839-1843
  • 6 Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.  Hepatology. 1998;  28 296-301
  • 7 Gregorio G V, Portmann B, Karani J et al.. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology. 2001;  33 544-553
  • 8 Abdo A A, Bain V G, Kichian K, Lee S S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome.  Hepatology. 2002;  36 1393-1399
  • 9 Beuers U. Hepatic overlap syndromes.  J Hepatol. 2005;  42(suppl 1) S93-S99
  • 10 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 929-938
  • 11 Kanzler S, Weidemann C, Gerken G et al.. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis.  J Hepatol. 1999;  31 635-640
  • 12 Terjung B, Bogsch F, Klein R et al.. Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis.  Eur J Med Res. 2004;  9 439-448
  • 13 Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.  Gut. 2004;  53 865-870
  • 14 Vierling J M. Primary biliary cirrhosis and autoimmune cholangiopathy.  Clin Liver Dis. 2004;  8 177-194
  • 15 Heathcote E J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.  Hepatology. 2000;  31 1005-1013
  • 16 Wiesner R H, LaRusso N F, Ludwig J, Dickson E R. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis.  Gastroenterology. 1985;  88 108-114
  • 17 Ludwig J, Colina F, Poterucha J J. Granulomas in primary sclerosing cholangitis.  Liver. 1995;  15 307-312
  • 18 Lee Y M, Kaplan M M. Primary sclerosing cholangitis.  N Engl J Med. 1995;  332 924-933
  • 19 Heathcote J. Autoimmune cholangitis.  Gut. 1997;  40 440-442
  • 20 Brunner G, Klinge O. A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis) [in German].  Dtsch Med Wochenschr. 1987;  112 1454-1458
  • 21 Ben-Ari Z, Dhillon A P, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis.  Hepatology. 1993;  18 10-15
  • 22 Sherlock S. Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity?.  Mayo Clin Proc. 1998;  73 184-190
  • 23 Czaja A J, Carpenter H A, Santrach P J, Moore S B. Autoimmune cholangitis within the spectrum of autoimmune liver disease.  Hepatology. 2000;  31 1231-1238
  • 24 Michieletti P, Wanless I R, Katz A et al.. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.  Gut. 1994;  35 260-265
  • 25 Taylor S L, Dean P J, Riely C A. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis.  Am J Surg Pathol. 1994;  18 91-99
  • 26 Goodman Z D, McNally P R, Davis D R, Ishak K G. Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases.  Dig Dis Sci. 1995;  40 1232-1242
  • 27 Omagari K, Ikuno N, Matsuo I et al.. Autoimmune cholangitis syndrome with a bias towards primary biliary cirrhosis.  Pathology. 1996;  28 255-258
  • 28 Invernizzi P, Crosignani A, Battezzati P M et al.. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis.  Hepatology. 1997;  25 1090-1095
  • 29 Kinoshita H, Omagari K, Whittingham S et al.. Autoimmune cholangitis and primary biliary cirrhosis-an autoimmune enigma.  Liver. 1999;  19 122-128
  • 30 Neuberger J, Thomson R. PBC and AMA-what is the connection?.  Hepatology. 1999;  29 271-276
  • 31 Miyakawa H, Tanaka A, Kikuchi K et al.. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens.  Hepatology. 2001;  34 243-248
  • 32 Tsuneyama K, Van De Water J, Van Thiel D et al.. Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis.  Hepatology. 1995;  22 1440-1446
  • 33 Ikuno N, Scealy M, Davies J M et al.. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display.  Hepatology. 2001;  34 478-486
  • 34 Gordon S C, Quattrociocchi-Longe T M, Khan B A et al.. Antibodies to carbonic anhydrase in patients with immune cholangiopathies.  Gastroenterology. 1995;  108 1802-1809
  • 35 Ohana M, Okazaki K, Hajiro K, Uchida K. Antilactoferrin antibodies in autoimmune liver diseases.  Am J Gastroenterol. 1998;  93 1334-1339
  • 36 Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote E J. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis?.  Dig Dis Sci. 2000;  45 2018-2021
  • 37 Muratori L, Muratori P, Zauli D et al.. Antilactoferrin antibodies in autoimmune liver disease.  Clin Exp Immunol. 2001;  124 470-473
  • 38 Lacerda M A, Ludwig J, Dickson E R, Jorgensen R A, Lindor K D. Antimitochondrial antibody-negative primary biliary cirrhosis.  Am J Gastroenterol. 1995;  90 247-249
  • 39 Kim W R, Poterucha J J, Jorgensen R A et al.. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.  Hepatology. 1997;  26 22-26
  • 40 James O F, Bhopal R, Howel D, Gray J, Burt A D, Metcalf J V. Primary biliary cirrhosis once rare, now common in the United Kingdom?.  Hepatology. 1999;  30 390-394
  • 41 Kim W R, Lindor K D, Locke III G R et al.. Epidemiology and natural history of primary biliary cirrhosis in a US community.  Gastroenterology. 2000;  119 1631-1636
  • 42 Boberg K M, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population.  Scand J Gastroenterol. 1998;  33 99-103
  • 43 Geubel A P, Baggenstoss A H, Summerskill W H. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome.  Gastroenterology. 1976;  71 444-449
  • 44 Kloppel G, Seifert G, Lindner H, Dammermann R, Sack H J, Berg P A. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity.  Virchows Arch A Pathol Anat Histol. 1977;  373 143-160
  • 45 Gheorghe L, Iacob S, Gheorghe C et al.. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease.  Eur J Gastroenterol Hepatol. 2004;  16 585-592
  • 46 Lohse A W, zum Buschenfelde K H, Franz B, Kanzler S, Gerken G, Dienes H P. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals.  Hepatology. 1999;  29 1078-1084
  • 47 Yamamoto K, Terada R, Okamoto R et al.. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease.  J Gastroenterol. 2003;  38 52-59
  • 48 Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases.  Clin Rev Allergy Immunol. 2005;  28 115-133
  • 49 Kanzler S, Bozkurt S, Herkel J, Galle P R, Dienes H P, Lohse A W. Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome) [in German].  Dtsch Med Wochenschr. 2001;  126 450-456
  • 50 Beuers U. Overlap syndromes. In: Gershwin ME, Vierling, JM, Manns, MP Liver Immunology Philadelphia, PA; Hanley & Belfus 2003: 363-371
  • 51 Leuschner U. Autoimmunkrankheiten der Leber und Overlapsyndrome. Bremen, Germany; UNI-MED Verlag 2001
  • 52 Duclos-Vallee J C, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A.  Dig Dis Sci. 1995;  40 1069-1073
  • 53 el-Shabrawi M, Wilkinson M L, Portmann B et al.. Primary sclerosing cholangitis in childhood.  Gastroenterology. 1987;  92 1226-1235
  • 54 Rabinovitz M, Demetris A J, Bou-Abboud C F, Van Thiel D H. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis.  Dig Dis Sci. 1992;  37 1606-1611
  • 55 Lawrence S P, Sherman K E, Lawson J M, Goodman Z D. A 39 year old man with chronic hepatitis.  Semin Liver Dis. 1994;  14 97-105
  • 56 Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children.  J Pediatr. 1994;  124 49-56
  • 57 Wilschanski M, Chait P, Wade J A et al.. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis.  Hepatology. 1995;  22 1415-1422
  • 58 Gohlke F, Lohse A W, Dienes H P et al.. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.  J Hepatol. 1996;  24 699-705
  • 59 McNair A N, Moloney M, Portmann B C, Williams R, McFarlane I G. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases.  Am J Gastroenterol. 1998;  93 777-784
  • 60 van Buuren H R, van Hoogstraten H JE, Terkivatan T, Schalm S W, Vleggaar F P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis.  J Hepatol. 2000;  33 543-548
  • 61 Kaya M, Angulo P, Lindor K D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system.  J Hepatol. 2000;  33 537-542
  • 62 Chazouilleres O. Diagnosis of primary sclerosing cholangitis-autoimmune hepatitis overlap syndrome: to score or not to score?.  J Hepatol. 2000;  33 661-663
  • 63 Beuers U, Spengler U, Kruis W et al.. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.  Hepatology. 1992;  16 707-714
  • 64 Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.  Scand J Gastroenterol Suppl. 1994;  204 59-61
  • 65 Lindor K D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.  N Engl J Med. 1997;  336 691-695
  • 66 Mitchell S A, Bansi D S, Hunt N, Von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907
  • 67 Czaja A J, Carpenter H A. Autoimmune hepatitis with incidental histologic features of bile duct injury.  Hepatology. 2001;  34 659-665
  • 68 Li C P, Tong M J, Hwang S J et al.. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid.  J Gastroenterol Hepatol. 2000;  15 95-98
  • 69 Rubel L R, Seeff L B, Patel V. Primary biliary cirrhosis-primary sclerosing cholangitis overlap syndrome.  Arch Pathol Lab Med. 1984;  108 360-361
  • 70 Burak K W, Urbanski S J, Swain M G. A case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases.  Dig Dis Sci. 2001;  46 2043-2047
  • 71 Zanger U M, Hauri H P, Loeper J, Homberg J C, Meyer U A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.  Proc Natl Acad Sci USA. 1988;  85 8256-8260
  • 72 Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.  J Clin Invest. 1989;  83 1066-1072
  • 73 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest. 1991;  88 1370-1378
  • 74 Manns M P, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.  Hepatology. 1997;  26 1054-1066
  • 75 Lunel F, Abuaf N, Frangeul L et al.. Liver/kidney microsome antibody type 1 and hepatitis C virus infection.  Hepatology. 1992;  16 630-636
  • 76 Pawlotsky J M, Ben Yahia M, Andre C et al.. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.  Hepatology. 1994;  19 841-848
  • 77 Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection.  J Hepatol. 1999;  31 210-216

Ulrich BeuersM.D. 

Department of Medicine II-Grosshadern, Ludwig Maximilians-University of Munich

Marchioninistrasse 15, 81377 Munich, Germany

Email: Beuers@med.uni-muenchen.de